

Colon Cancer - Pipeline Review, H1 2020

<https://marketpublishers.com/r/C28F485BBE4EN.html>

Date: June 2020

Pages: 1184

Price: US\$ 2,500.00 (Single User License)

ID: C28F485BBE4EN

Abstracts

Colon Cancer - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer - Pipeline Review, H1 2020, provides an overview of the Colon Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colon Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III,

Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 22, 53, 8, 206, 30 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 2, 43 and 13 molecules, respectively.

Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Colon Cancer - Overview

Colon Cancer - Therapeutics Development

Colon Cancer - Therapeutics Assessment

Colon Cancer - Companies Involved in Therapeutics Development

Colon Cancer - Drug Profiles

Colon Cancer - Dormant Projects

Colon Cancer - Discontinued Products

Colon Cancer - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Colon Cancer, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Colon Cancer - Pipeline by 1ST Biotherapeutics Inc, H1 2020

Colon Cancer - Pipeline by ABL Bio Inc, H1 2020

Colon Cancer - Pipeline by ACF Pharmaceuticals LLC, H1 2020

Colon Cancer - Pipeline by Actinium Pharmaceuticals Inc, H1 2020

Colon Cancer - Pipeline by Actym Therapeutics Inc, H1 2020

Colon Cancer - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2020

Colon Cancer - Pipeline by Aduro BioTech Inc, H1 2020

Colon Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H1 2020

Colon Cancer - Pipeline by Adze Biotechnology Inc, H1 2020

Colon Cancer - Pipeline by Aeglea BioTherapeutics Inc, H1 2020

Colon Cancer - Pipeline by Trillium Therapeutics Inc, H1 2020

Colon Cancer - Pipeline by TVAX Biomedical Inc, H1 2020

Colon Cancer - Pipeline by Tychon Bioscience Inc, H1 2020

Colon Cancer - Pipeline by Tyg Oncology Ltd, H1 2020

Colon Cancer - Pipeline by Tyme Technologies Inc, H1 2020

Colon Cancer - Pipeline by Vault Pharma Inc, H1 2020

Colon Cancer - Pipeline by Veana Therapeutics LLC, H1 2020

Colon Cancer - Pipeline by Vernalis R&D Ltd, H1 2020

Colon Cancer - Pipeline by Viomedix LLC, H1 2020

Colon Cancer - Pipeline by Viracta Therapeutics Inc, H1 2020

Colon Cancer - Pipeline by Virogin Biotech Ltd, H1 2020

Colon Cancer - Pipeline by Well Marker Bio Co Ltd, H1 2020

Colon Cancer - Pipeline by Wellmarker Bio Co Ltd, H1 2020
Colon Cancer - Pipeline by Westwood Bioscience Inc, H1 2020
Colon Cancer - Pipeline by WntResearch AB, H1 2020
Colon Cancer - Pipeline by Wuhan Binhui Biotechnology Co Ltd, H1 2020
Colon Cancer - Pipeline by Wuhan YZY Biopharma Co Ltd, H1 2020
Colon Cancer - Pipeline by XOMA Corp, H1 2020
Colon Cancer - Pipeline by Y-mAbs Therapeutics Inc, H1 2020
Colon Cancer - Pipeline by Yuhan Corp, H1 2020
Colon Cancer - Pipeline by Zenith Epigenetics Ltd, H1 2020
Colon Cancer - Pipeline by Zovis Pharmaceuticals, H1 2020
Colon Cancer - Dormant Projects, H1 2020
Colon Cancer - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Colon Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

1ST Biotherapeutics Inc
ABL Bio Inc
ACF Pharmaceuticals LLC
Actinium Pharmaceuticals Inc
Actym Therapeutics Inc
Adgero Biopharmaceuticals Holdings Inc
Aduro BioTech Inc
Advanced Cancer Therapeutics LLC
Adze Biotechnology Inc
Aeglea BioTherapeutics Inc
Affimed GmbH
Agenus Inc
AGV Discovery SAS
AIMM Therapeutics BV
Alfasigma SpA
Alligator Bioscience AB
Alpine Immune Sciences Inc
Amarin Corp Plc
Ambrx Inc
Amrita Therapeutics
ANP Technologies Inc

Aphios Corp
Apollomics Inc
AptaBio Therapeutics Inc
Arbele Ltd
Ariz Precision Medicine Inc
Ascelia Pharma AB
AskAt Inc
aTyr Pharma Inc
Aurigene Discovery Technologies Ltd
Avican Inc
Avidin Ltd
Bayer AG
Baylx Inc
Beijing Fogangren Bio-Pharm Tech Co Ltd
BeyondSpring Inc
Binjiang Pharma, Inc.
Biogazelle NV
BioMed Valley Discoveries Inc
Biomunex Pharmaceuticals
Black Diamond Therapeutics Inc
Bliss Biopharmaceutical (Hangzhou) Co Ltd
Blueprint Medicines Corp
Boehringer Ingelheim International GmbH
Bold Therapeutics Inc
Calidi Biotherapeutics Inc
Can-Fite BioPharma Ltd
Cancer Prevention Pharmaceuticals Inc
Cancure Ltd
Canget BioTekpharma LLC
CARsgen Therapeutics Ltd
Celldex Therapeutics Inc
Collective BioTherapy Inc
Celprogen Inc
CG Oncology Inc
ChemoCentryx Inc
Chipscreen Biosciences Ltd
Clover Biopharmaceuticals
CMG Pharmaceutical Co Ltd
Codiak BioSciences Inc

Convert Pharmaceuticals SA
CStone Pharmaceuticals Co Ltd
Cureport Inc
CV6 Therapeutics (Ni) Ltd
Cytocom Inc
Cytodyn Inc
CytomX Therapeutics Inc
CZ BioMed Corp
DEKK-TEC Inc
Diazon Pharmaceuticals Inc
DiNonA Inc
Disulfican Ltd
Diverse Biotech Inc
Domainex Ltd
Dracen Pharmaceuticals Inc
Eli Lilly and Co
Emcure Pharmaceuticals Ltd
EncuraGen Inc
Enochian Biosciences Inc
EntreChem SL
EnzymeBioSystems
Epigene Therapeutics Inc
Ervaxx Ltd
Etubics Corp
Evelo Biosciences Inc
Evestra Inc
Evotec SE
F-star Biotechnology Ltd
Felicitex Therapeutics Inc
For-Robin Inc
Fujifilm Holdings Corp
Fusion Antibodies Plc
G1 Therapeutics Inc
GeoVax Labs Inc
GlaxoSmithKline Plc
GlycaNova AS
GlycoMimetics Inc
GlycoNex Inc
GlyTR Therapeutics Inc

GO Therapeutics Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Hamlet Pharma AB
HengRui YuanZheng Bio-Technology Co Ltd
Hibiskus Biopharma Inc
HitGen LTD
Horizon Therapeutics Plc
Huabo Biopharm Co Ltd
Hummingbird Bioscience Pte Ltd
I-Mab Biopharma Co Ltd
i2 Pharmaceuticals Inc
Ikena Oncology Inc
Ildong Pharmaceutical Co Ltd
ImCheck Therapeutics SAS
Immix BioPharma Inc
Immune Modulation Inc
Immunicum AB
ImmunityBio Inc
Immunos Therapeutics AG
Immunotope Inc
IMPACT Therapeutics Inc
Infinity Pharmaceuticals Inc
Inmune Bio Inc
Innate Pharma SA
Innopharmax Inc
Intensity Therapeutics Inc
InteRNA Technologies BV
iOmx Therapeutics AG
J-Pharma Co Ltd
JenKem Technology Co Ltd
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
JN Biosciences LLC
JW Pharmaceutical Corp
Kadmon Corp LLC
KAHR medical Ltd
Karyopharm Therapeutics Inc
Kineta Inc
Kitov Pharma Ltd

Kolon Life Science Inc
Kringle Pharma Inc
Kymab Ltd
LipoSeuticals Inc
Lixte Biotechnology Holdings Inc
MabVax Therapeutics Holdings Inc
Machavert Pharmaceuticals LLC
MacroGenics Inc
Mateon Therapeutics Inc
MaxiVAX SA
Medicenna Therapeutics Corp
Medicon Pharmaceuticals Inc
Merck & Co Inc
Merck KGaA
MicroQuin Ltd
Midissia Therapeutics Inc
Millennium Pharmaceuticals Inc
Multimmune GmbH
MultiVir Inc
Nanjing Jinsirui Biotechnology Co Ltd
NED Biosystems Inc
Northern Biologics Inc
Northwest Biotherapeutics Inc
Novartis AG
Novita Pharmaceuticals Inc
Novonco Pharmaceuticals Inc
Obio Technology (Shanghai) Corp Ltd
Oceanyx Pharmaceuticals Inc
Omeros Corp
Oncocross Co Ltd
Oncorus Inc
Oncovir Inc
Oncoxx Biotech Srl
Oneness Biotech Co Ltd
Ono Pharmaceutical Co Ltd
Orano Med LLC
Orpheus Therapeutics Inc
Pacylex Pharmaceuticals Inc
Patrys Ltd

Pfizer Inc
PharmAbcine Inc
PharmaCyte Biotech Inc
Phenex Pharmaceuticals AG
Photolitec LLC
PHusis Therapeutics Inc
Pionyr Immunotherapeutics Inc
PNB Vesper Life Science Pvt Ltd
Primetime Life Sciences LLC
Protexase Therapeutics Inc
Provecs Medical GmbH
Provectus Biopharmaceuticals Inc
PTC Therapeutics Inc
Qilu Puget Sound Biotherapeutics Corp
Qu Biologics Inc
Resarci Therapeutics LLC
Resonant Therapeutics Inc
Rexahn Pharmaceuticals Inc
Riptide Bioscience Inc
Rubius Therapeutics Inc
Sagimet Biosciences
Sareum Holdings Plc
Savoy Pharmaceuticals Inc
Schrodinger LLC
Scopus BioPharma Inc
SEEKYO Therapeutics
Senex Biotechnology
SetLance srl
Shanghai Junshi Bioscience Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shaperon Inc
Shattuck Labs Inc
Shionogi & Co Ltd
Shouyao Holding Co Ltd
Sichuan Huiyang Life Science and Technology Corp
SideROS
SignPath Pharma Inc
Silicon Therapeutics LLC
Somantix BV

Soricimed Biopharma Inc
Sorrento Therapeutics Inc
Sphaera Pharma Pte Ltd
Spring Bank Pharmaceuticals Inc
Stcube Inc
Sun BioPharma Inc
Suzhou Sinovent Pharmaceuticals Co Ltd
Suzhou Stainwei Biotech Inc
Tactical Therapeutics Inc
Taiho Pharmaceutical Co Ltd
Takis Srl
Talapo Therapeutics Inc
TargaGenix Inc
Tarus Therapeutics Inc
TenCure Ltd
TeneoBio Inc
TheraBioPhama
Theralase Technologies Inc
Theravectys SA
Tianjin Hengjia Biotechnology Development Co Ltd
Tiziana Life Sciences Plc
Toray Industries Inc
Transcenta Holding Ltd
Transgene Biotek Ltd
Transgene SA
Trillium Therapeutics Inc
TVAX Biomedical Inc
Tychon Bioscience Inc
Tyg Oncology Ltd
Tyme Technologies Inc
Vault Pharma Inc
Veana Therapeutics LLC
Vernalis R&D Ltd
Viomedix LLC
Viracta Therapeutics Inc
Virogin Biotech Ltd
Well Marker Bio Co Ltd
Wellmarker Bio Co Ltd
Westwood Bioscience Inc

WntResearch AB
Wuhan Binhui Biotechnology Co Ltd
Wuhan YZY Biopharma Co Ltd
XOMA Corp
Y-mAbs Therapeutics Inc
Yuhan Corp
Zenith Epigenetics Ltd
Zovis Pharmaceuticals

I would like to order

Product name: Colon Cancer - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/C28F485BBE4EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C28F485BBE4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970